BEIJING (Reuters) – China’s National Drug Administration has granted Merck’s KEYTRUDA therapy a licence for first-line treatment of certain stomach cancer patients in the country.
Merck is known as MSD outside the United States and Canada.
(Reporting by Beijing newsroom; Editing by David Goodman)
Comments